公开(公告)号：US12083192B2

公开(公告)日：2024-09-10

申请号：US16766009

申请日：2018-12-04

Applicant: Actinium Pharmaceuticals, Inc.

Inventor： Mark Berger

IPC: A61K51/10 ,  A61K31/10 ,  A61K31/198 ,  A61K31/675 ,  A61K31/7076 ,  A61P35/00 ,  A61P35/02 ,  C07K16/28 ,  C12Q1/6886 ,  A61K39/00

CPC classification number: A61K51/1033 ,  A61K31/10 ,  A61K31/198 ,  A61K31/675 ,  A61K31/7076 ,  A61K51/1069 ,  A61P35/00 ,  A61P35/02 ,  C07K16/2803 ,  C12Q1/6886 ,  A61K2039/505 ,  C07K2317/24 ,  C12Q2600/156

Abstract: Methods for treating a proliferative disease in hematologic malignancy in a subject having a complex karyotype by administering an effective amount of an immunotherapy which includes a targeting agent for an epitope of CD33. The proliferative disease may be a hematological disease or disorder such as multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm. The effective amount of the anti-CD33 targeting agent may be an amount sufficient to induce myeloconditioning or an amount to induce myeloablation. The methods may further include transplanting allogeneic stem cells to the patient after administration of the anti-CD33 targeting agent.

公开(公告)号：US20240216359A1

公开(公告)日：2024-07-04

申请号：US18600993

申请日：2024-03-11

Applicant: GMP BIOTECHNOLOGY LIMITED

Inventor： Vuong TRIEU

IPC: A61K31/485 ,  A61K9/00 ,  A61K31/10 ,  A61K31/7125 ,  A61K45/06 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/22 ,  A61P15/00 ,  A61P15/10 ,  A61P25/00 ,  C12N15/113

CPC classification number: A61K31/485 ,  A61K9/0043 ,  A61K31/10 ,  A61K31/7125 ,  A61K45/06 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/186 ,  A61K47/22 ,  A61P15/00 ,  A61P15/10 ,  A61P25/00 ,  C12N15/1136 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2320/31

Abstract: This invention relates to methods, compositions and uses of medicaments for treating or ameliorating the symptoms of neurological disorders, such as Parkinson's Disease and Alzheimer's Disease. These purposes can be achieved with formulations of agents for inhibiting or suppressing expression of TGF-β, alone or in combination with formulations of agents based on apomorphine.

公开(公告)号：US20240216326A1

公开(公告)日：2024-07-04

申请号：US18557089

申请日：2022-04-30

Applicant: NOON AESTHETICS M.R. LTD.

Inventor： Masha Minkin ,  Eran Rosman

IPC: A61K31/327 ,  A61K9/16 ,  A61K31/10 ,  A61K31/19 ,  A61K31/20 ,  A61K33/14 ,  A61K47/10 ,  A61P17/10

CPC classification number: A61K31/327 ,  A61K9/16 ,  A61K31/10 ,  A61K31/19 ,  A61K31/20 ,  A61K33/14 ,  A61K47/10 ,  A61P17/10

Abstract: Compositions comprising benzoyl peroxide, azelaic acid, a strontium salt, and methylsulfonylmethane (MSM) are provided, formulated as one or more dosage forms, wherein at least one dosage form comprises both benzoyl peroxide and azelaic acid. These compositions are formulated as cosmetic or medicinal products useful in treating skin diseases, disorders or conditions which may benefit form topical co-administration of BPO and azelaic acid. These skin care products provide dermal shielding against neurogenic inflammation, stinging, itching, burning, redness, irritation, and/or other sensations and feelings associated with topical application of BPO and/or azelaic acid.

公开(公告)号：US20230398060A1

公开(公告)日：2023-12-14

申请号：US18033104

申请日：2021-05-19

Applicant: MIG USA, LLC

Inventor： Adnan Mjalli ,  Bill Hitchcock

IPC: A61K9/00 ,  A61K9/06 ,  A61K47/36 ,  A61K31/192 ,  A61K31/10 ,  A61K31/616 ,  A61K31/00 ,  A61K31/137 ,  A61K31/606 ,  A61K31/196 ,  A61P29/00

CPC classification number: A61K9/0019 ,  A61K9/06 ,  A61K47/36 ,  A61K31/192 ,  A61K31/10 ,  A61K31/616 ,  A61K31/658 ,  A61K31/137 ,  A61K31/606 ,  A61K31/196 ,  A61P29/00

Abstract: Disclosed are compositions and methods for the treatment of pain and/or inflammation. In certain embodiments, the disclosed compositions and methods have anti-inflammatory activity. In some embodiments, the disclosed compositions and methods have analgesic activity. The present disclosure provides that two non-steroidal anti-inflammatory agents, as for example, 2-(4-isobutylphenyl)propanoic acid (ibuprofen), acetylsalicylic acid (aspirin), a muscle relaxant, and cannabidiol (CBD) can be used in combination in a topical formulation as an effective analgesic and/or anti-inflammatory agent.

公开(公告)号：US11752121B2

公开(公告)日：2023-09-12

申请号：US17886354

申请日：2022-08-11

Applicant: NPI, LLC

Inventor： Charles Ryan Yates ,  Cameron Volpe Fili ,  Ling Lin ,  Jonathan Chapman ,  Hector L. Lopez

IPC: A61K31/197 ,  A23L33/105 ,  A61P3/06 ,  A61P3/10 ,  A61K31/10 ,  A61K31/36 ,  A61K36/185

CPC classification number: A61K31/197 ,  A23L33/105 ,  A61K31/10 ,  A61K31/36 ,  A61K36/185 ,  A61P3/06 ,  A61P3/10

Abstract: Nutritionally acceptable non-lipid compositions and methods are presented that modulate lipid metabolism, and especially increase LPC concentrations. Consequently, the compositions and methods presented herein will facilitate DHA transport to neural and retinal tissues as well as LA availability for cardiolipin synthesis.

公开(公告)号：US20230263853A1

公开(公告)日：2023-08-24

申请号：US18017133

申请日：2021-07-01

Applicant: HAYNE LANE LTD

Inventor： James BRINICOMBE

IPC: A61K36/8962 ,  A61K9/00 ,  A61K31/10 ,  A61K31/198 ,  A61K36/02 ,  A61P33/14

CPC classification number: A61K36/8962 ,  A61K9/0056 ,  A61K31/10 ,  A61K31/198 ,  A61K36/02 ,  A61P33/14

Abstract: The present invention relates to an ectoparasiticide veterinary composition comprising a nutraceutical sourced from Allium sativum comprising at least one compound of the formula (I): wherein n is at least 4 and in which R1 is selected from the group comprising: hydrogen; halogens; substituted or unsubstituted C1-5 alkyl groups; substituted or unsubstituted phenyl groups; carboxy group; carboalkoxy groups; hydroxymethyl; and trimethylsilylmethyl.

公开(公告)号：US20230255959A1

公开(公告)日：2023-08-17

申请号：US18191810

申请日：2023-03-28

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak SAMPATH ,  Christian KLEIN ,  Wayne John FAIRBROTHER

IPC: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/395

CPC classification number: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/39558 ,  A61K2039/545

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US20230225990A1

公开(公告)日：2023-07-20

申请号：US18002433

申请日：2021-06-21

Applicant: Evonik Operations GmbH

Inventor： Vincent HESS ,  Juliano Cesar DE PAULA DORIGAM ,  Joris MICHIELS

IPC: A61K31/10 ,  A23K20/105 ,  A23K50/75 ,  A61P39/00 ,  A61K9/00

CPC classification number: A61K31/10 ,  A23K20/105 ,  A23K50/75 ,  A61P39/00 ,  A61K9/0056

Abstract: Dimethyl sulfone may be used in the treatment of heat stress in poultry by oral administration, wherein the dimethyl sulfone is administered to chronically heat stressed poultry. The poultry may be exposed to a temperature of more than 27° C., or at least 30° C., optionally for at least 5 hours a day. The poultry may be exposed to a relative air humidity of at least 40% on average. The dimethyl sulfone is administered to poultry in a starter, grower, and/or finisher phase.

公开(公告)号：US11672755B2

公开(公告)日：2023-06-13

申请号：US17789530

申请日：2020-12-31

Applicant: WANKA TANKA LTD.

Inventor： Amnon Vardi

IPC: A61K9/00 ,  A61K47/32 ,  A61K47/44 ,  A61K47/10 ,  A61K47/34 ,  A61K31/198 ,  A61K31/737 ,  A61K31/10 ,  A61K38/39 ,  A61K31/12 ,  A61K36/53 ,  A61K31/714 ,  A61K31/405 ,  A61K36/88 ,  A61K36/38 ,  A61K31/197 ,  A61K31/7008

CPC classification number: A61K9/0017 ,  A61K31/10 ,  A61K31/12 ,  A61K31/197 ,  A61K31/198 ,  A61K31/405 ,  A61K31/7008 ,  A61K31/714 ,  A61K31/737 ,  A61K36/38 ,  A61K36/53 ,  A61K36/88 ,  A61K38/39 ,  A61K47/10 ,  A61K47/32 ,  A61K47/34 ,  A61K47/44

Abstract: A plastic material for extended release of a bio-active agent, the plastic material comprising a structural polymer, at least one bio-active ingredient embedded within the structural polymer as solid islands, a liquid binding material embedded within the structural polymer as granules, and a carrier liquid absorbed within the liquid-absorbent material. The carrier liquid may be sufficiently non-compatible with the structural polymer so that at least a portion of the carrier liquid is released from the liquid-absorbent material through the structural polymer to an outer surface of the plastic material over a period of time, such as a week or more, a month or more, or about three months. The bio-active agent comprised in the at least one bio-active ingredient may be sufficiently soluble in the carrier liquid at room or body temperature so that the carrier liquid released to the outer surface comprises the bio-active agent in solution.

公开(公告)号：US20190192658A1

公开(公告)日：2019-06-27

申请号：US16234380

申请日：2018-12-27

Applicant: Melissa Ward

Inventor： Melissa Ward

IPC: A61K45/06 ,  A61K31/05 ,  A61K31/047 ,  A61K31/045 ,  A61K36/899 ,  A61K36/53 ,  A61K36/28 ,  A61K31/355 ,  A61K47/32 ,  A61K36/886 ,  A61K31/10 ,  A61K31/133 ,  A61K36/76 ,  A61K36/81 ,  A61K36/31 ,  A61P29/00

CPC classification number: A61K45/06 ,  A61K31/045 ,  A61K31/047 ,  A61K31/05 ,  A61K31/10 ,  A61K31/133 ,  A61K31/355 ,  A61K36/28 ,  A61K36/31 ,  A61K36/53 ,  A61K36/76 ,  A61K36/81 ,  A61K36/886 ,  A61K36/899 ,  A61K47/32 ,  A61P29/00

Abstract: A topical pain relief composition including a topical cream that may be rubbed on virtually any area in need of pain relief. It offers an analgesic formulated for relieving pain in the joints or muscles. The composition includes a matrix including a water soluble active ingredient ranging from 20.7% to 25.2% total weight of the matrix, a water insoluble active ingredient ranging from 18.7% to 22.9% total weight of the matrix, and purified water ranging from 56% to 68.8% total weight of the matrix. A first-combination of phoenoxyethanol, caprynyl glycol and, sorbic acid ranging from 1.08% to 1.32% of total weight of the matrix is included. Further, a second-combination is provided of oryza sativa bran extract, rosmarinus officinalis leaf extract, helianthus anuus extract and, tocopherol ranging from 0.9% to 1.1% of total weight of the matrix functional as a suitable the topical pain relief composition.